ASSESSMENT OF COGNITIVE AND BRAIN METABOLIC CHANGES IN RESPONSE TO IAS TREATMENT

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。前列腺癌是男性最常见的癌症。间歇性雄激素抑制（IAS）是诊断患有前列腺癌的男性的常见治疗策略，其将雄激素戒断（6-9个月）与“停止治疗”期进行循环，使睾酮水平恢复到生理水平。然后，当前列腺特异性抗原（PSA）达到依赖于主要治疗的阈值时，恢复治疗。这项拟议的研究检查了接受IAS治疗的非转移性前列腺癌患者和健康男性的情绪，认知，脑代谢和Abeta水平的变化，并将使用行为和脑代谢方法来评估变化。我们还将研究APOE状态作为认知变化的可能调节因素

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prostate cancer is the most common form of cancer diagnosed in men. Intermittent androgen suppression (IAS) is a common treatment strategy for men diagnosed with prostate cancer that cycles androgen withdrawal (6-9 months) with an "off treatment" period allowing testosterone levels to return to physiological levels. Treatment is then reinstated as the prostate specific antigen (PSA) reaches a threshold dependent upon primary therapy. The proposed study examines changes in mood, cognition, brain metabolism, and Abeta levels in men with non-metastatic prostate cancer undergoing IAS treatment and healthy men, and will use both behavioral and brain metabolic methods to assess change. We will also examine APOE status as a possible modulating factor for cognitive changes